INTRODUCTION
============

Zinc has various effects on the immune system and its deficiency increases the risk of infections \[[@R1],[@R2]\]. In developing countries, there is evidence that zinc supplementation may reduce the risk of the common cold and pneumonia in children \[[@R2]-[@R4]\]. Although such studies indicate that zinc plays an important role in the immune system, those findings cannot be extrapolated to the developed countries where there is no wide spread zinc deficiency. For example, in France and in the UK, multivitamin-mineral tablets containing 15 or 20 mg/day of zinc had no effect on the incidence of respiratory infections of elderly people \[[@R5],[@R6]\].

Interest in zinc lozenges (tablets intended to be dissolved slowly in the mouth) for treating the common cold started from the serendipitous observation that a cold of a 3-year-old girl with leukemia disappeared when she dissolved a therapeutic zinc tablet in her mouth instead of swallowing it \[[@R7]\]. This finding led to a series of controlled trials which have produced conflicting results. The composition of zinc lozenges has varied and some of them contained substances which bind zinc ions tightly. Therefore, a low level of free zinc ions has been considered as one potential factor that might explain divergence in the results \[[@R8]-[@R15]\]. The mode of action of zinc in the oral cavity is not known. However, the fundamental questions in evaluating a potential treatment should be efficacy, safety and cost, whereas biological explanations and the effects on surrogate outcomes should be secondary issues \[[@R16]-[@R18]\].

The purpose of this systematic review is to examine the relationship between the total daily dose of zinc from the lozenges and the effect of the zinc lozenges on the duration of colds in patients who had natural common cold infections.

METHODS
=======

Search of the Trials
--------------------

Ovid MEDLINE (November 24, 2010) was searched using the free search terms "zinc" and "lozenge\$" which retrieved 67 records. The same search terms were used for SCOPUS (November 24, 2010; 107 records) and for the Cochrane Central Register of Controlled Trials (CENTRAL; November 24, 2010; 20 records). No language restrictions were used in the searches. The reference lists of the trials and reviews identified were also perused.

This systematic review was restricted to trials examining the therapeutic effect of zinc lozenges on natural common cold infections. As an inclusion criterion, a concurrent placebo group was required, because clinically relevant common cold outcomes are largely subjective, and explicitly different interventions (i.e., no placebo in one arm) might bias the comparison. Studies with adults and children were both included. Rather than exclude non-randomized trials, their influence was considered in a sensitivity analysis. Eleven publications fulfilling the inclusion criteria were identified \[[@R7],[@R19]-[@R28]\] (Table **[1](#T1){ref-type="table"}**, see Supplementary Material 1 for a flow diagram of the search and Supplementary Material 2 for a summary of the main characteristics of the included trials). One publication reported three zinc lozenge arms which were compared with one placebo arm \[[@R23]\], so that the number of identified zinc lozenge *vs* placebo comparisons was 13 (Table **[1](#T1){ref-type="table"}**). One zinc lozenge study was excluded because the lozenge was used with a nasal spray and thus the comparison was not specific to the lozenge \[[@R29]\]. No protocol was written for this systematic review.

To confirm that there are no further trials in addition to those listed in Table **[1](#T1){ref-type="table"}**, a cited reference search was also carried out (Web of Science, November 24, 2010) using the 11 identified publications as cited references, because inaccuracy in coding might hamper the identification of relevant trials in MEDLINE, SCOPUS and CENTRAL. Since all new trials on a given topic most probably refer to one or more earlier trials on the same topic, this provides a further approach for searching the literature. No additional trials were identified by screening the 269 publications that cited the zinc lozenge reports of Table **[1](#T1){ref-type="table"}**.

Calculation of the Daily Zinc Dosage
------------------------------------

The total daily dose of elemental zinc from the lozenges was calculated as the product of the zinc dose per lozenge and the counted or planned number of lozenges per day (Table **[1](#T1){ref-type="table"}**; see Supplementary Material 2 for the calculations). In six trials, the number of lozenges was counted \[[@R20]-[@R22],[@R24]-[@R26]\]. In the other trials, the usage recommended was the basis for the calculation of the total zinc dosage; for example, description of the dosage as "every 2 hr awake" was interpreted as 9 times per day.

Statistical Methods
-------------------

Some earlier reviews on the effect of zinc lozenges on common cold symptoms calculated the effect of zinc on common cold duration on the absolute scale, i.e., as the difference in days in the cold duration \[[@R11],[@R13],[@R14]\]. However, Table **[1](#T1){ref-type="table"}** shows a substantial variation in the duration of colds in the placebo groups, from 5.1 days \[[@R22]\] to 9.0 days \[[@R27]\] and 10.8 days \[[@R7]\]. Although part of this variation is evidently caused by random variation, it is also caused by actual variations in the severity of disease in different patient groups and in differences in outcome definitions. In this study, the relative effect of zinc on the common cold duration was calculated in percentages, because the relative effect partly adjusts for the variations between patient groups and outcome definitions. Previously, the calculation of relative effect instead of the absolute effect led to stronger evidence that vitamin C supplementation decreases the duration of the common cold \[[@R30],[@R31]\]. Therefore, the relative effect is used in the Cochrane review on vitamin C and the common cold \[[@R32]\].

Two different approaches were used to evaluate the findings of the zinc lozenge trials: 1) combining the P-values by using the Fisher method \[[@R33],[@R34]\] and 2) pooling the study results by using the RevMan program (version 5) \[[@R35]\].

The P-values of Table **[1](#T1){ref-type="table"}** were combined by using the Fisher method, which is based on the relation that --2×log(P) follows the χ^2^-distribution with 2 degrees of freedom, with the P-value given in the 1-tailed form \[[@R33],[@R34]\]. Thus, the --2×log(P) values for all selected trials (N trials) are added, and the total follows the χ^2^-distribution with N×2 degrees of freedom, which gives the combined P-value for all the N trials. When appropriate data was published, the accurate P-values were calculated. For trials for which the P-value was not reported and could not be calculated, P = 0.5 was used, which conservatively assumes equality between the zinc lozenge and the placebo. Extracted or derived P-values are described in Supplementary Material 2. The combined P-values for selected groups of trials are calculated in Table **[2](#T2){ref-type="table"}**.

The benefit of the Fisher method of combining P-values is that it can be used for results that are reported on different scales and when limited data is available \[[@R33],[@R34]\]. For example, if one trial reports the duration with its standard deviation (SD) and another trial reports the number of participants who had colds lasting over 7 days, both of them measure the effect on common cold duration, but on different scales. Although no combined effect estimate can be calculated for such trials, the P-values of those two trials can be combined by using the Fisher method. Furthermore, if there is no difference between the study groups e.g. on the basis of considerable overlap in the survival graphs - even though mean and SD are not reported - the study can be included without making any assumptions about the mean and SD, since the lack of difference corresponds to P(1-tail) = 0.5. Some of the zinc lozenge trials did not report the mean duration of colds and its SD, but they reported the P-values for the comparison of the zinc and placebo groups. For these reasons, the Fisher method was used as one approach to test whether there is a difference between zinc and placebo groups.

A forest plot (Fig. **[1](#F1){ref-type="fig"}**) is an efficient way to show the results of several trials, and it was used as a second approach. However, this approach needs the mean and SD values for the zinc and placebo groups. Only three zinc lozenge studies reported the SD values \[[@R21],[@R22],[@R25]\]. One study reported the t-value for the comparison \[[@R20]\] and another reported the P-value \[[@R26]\], and the corresponding SD-values were calculated. Nine comparisons were reported as survival graphs, i.e. the number of participants who remained ill or were recovered as a function of time \[[@R7],[@R19],[@R23]-[@R25],[@R27],[@R28]\]. These graphs were measured and transformed to the distribution of the duration of colds, which yielded estimates of the mean and SD (Supplementary Material 3). In the analysis of the graphs, several imputations were needed, because the graphs usually did not continue until all patients were recovered. Since the forest-plot analysis required a number of subjective decisions, the Fisher method (above) provided a useful parallel method, because it required less subjective decisions. Nevertheless, sensitivity analyses showed that the conclusions of Fig. (**[1](#F1){ref-type="fig"}**) are robust to variation in the imputation approach (Supplementary Material 3). The forest plot (Fig. **[1](#F1){ref-type="fig"}**) was calculated by using the RevMan program of the Cochrane Collaboration (version 5), using the inverse-variance fixed-effect option \[[@R35]\]. The heterogeneity between trials was assessed by using the χ^2^ and I^2^ -tests \[[@R36]\]. The I^2^ -test examines the percentage of total variation across studies, that is due to heterogeneity rather than chance. A value of I^2^ greater than about 75% indicates a high level of heterogeneity.

RESULTS
=======

Thirteen placebo-controlled comparisons have examined the therapeutic effect of zinc lozenges on the duration of common cold episodes of natural origin (Table **[1](#T1){ref-type="table"}** and Fig **[1](#F1){ref-type="fig"}**). The total number of common cold episodes in these trials was 1407. All the 13 comparisons were double-blind, although this feature was not a selection criterion. Because of double-blinding, all trials used allocation concealment. Weissman *et al*. \[[@R28]\] used consecutive allocation, but all the other trials were randomized. All studies examined young and middle-aged adults, except the Macknin *et al*. \[[@R27]\] trial, which examined schoolchildren.

In Table **[1](#T1){ref-type="table"}**, the trials are ordered by the total daily quantity of elemental zinc obtained from the lozenges. There is a seven-fold variation in the total daily dose of zinc. There is also a considerable variation in the results. Seven comparisons found a statistically significant benefit from zinc lozenges, but six did not.

Smith *et al*. \[[@R19]\] did not observe a difference between the study groups in the duration of colds; however, they did find a significant reduction in the severity scores on days 4 to 7 of treatment with P(1-tail)=0.01. Eby *et al*. \[[@R7]\] did not report the mean or median duration, but they did report the number of participants who had no symptoms at the end of the 7-day trial, an outcome used for calculating the P-value in Table **[1](#T1){ref-type="table"}**. The duration of colds given in Table **[1](#T1){ref-type="table"}** for the Eby trial is based on the exponential model which they used to estimate the time at which half of their patients were cured.

Table **[1](#T1){ref-type="table"}** shows that a substantial proportion of the variation in the results can be explained by the daily zinc dosage. None of the five comparisons that used less than 75 mg/day of zinc found an effect of zinc lozenges, whereas seven of the eight comparisons which used over 75 mg/day of zinc found a statistically significant benefit, although the benefit in the Smith *et al*. trial was restricted to the symptom severity at the late phase of the colds.

The P-values of the individual trials are combined by using the Fisher method in Table **[2](#T2){ref-type="table"}**. Combining the P-values of all the 13 comparisons provides very strong evidence that the zinc lozenge and placebo groups differ over all the trials. However, the benefit of zinc is restricted to trials where the dose was greater than 75 mg/day. A significant effect by zinc lozenges is seen separately in three high-dose trials where zinc acetate was used and in five high-dose trials which used zinc salts other than acetate.

Fig. (**[1](#F1){ref-type="fig"}**) shows the forest plot of all 13 zinc lozenge comparisons. There is a highly significant heterogeneity between the 13 trials on the basis of both the χ^2^ and I^2^-tests, with χ^2^(12 df) = 109 and I^2^ = 89%. The trials are divided into the low and high dose subgroups as in Table **[2](#T2){ref-type="table"}** and the two subgroups are considerably different in their estimate of the zinc lozenge effect.

In the low-dose trials, there is no evidence of heterogeneity and all the low-dose comparisons are consistent with no effect of zinc lozenges. In the eight high-dose trials, the zinc lozenges reduce the duration of colds by 32% (95% CI: 27% to 37%) but there is strong evidence of heterogeneity within this high-dose subgroup (χ^2^(7 df) = 46 and I^2^ = 85%) (Fig. **[1](#F1){ref-type="fig"}**).

Pooling the three high dose (\>75 mg/day) zinc acetate trials gives a mean effect of 42% reduction in the duration of colds and no heterogeneity is seen between these trials (Table **[3](#T3){ref-type="table"}**). Five high dose (\>75 mg/day) trials used zinc salts other than acetate \[[@R7],[@R19],[@R20],[@R23],[@R24]\]. None of them reported the SD value, but SD was estimated from the published survival curves (Supplementary Material [3]{.ul}) \[[@R7],[@R19],[@R23],[@R24]\] or the reported t-value \[[@R20]\]. Pooling these five non-acetate trials gives a mean effect of 20% (95% CI: 12% to 28%) reduction in the duration of colds. However, there is significant heterogeneity between these five non-acetate trials (χ^2^(4 df) = 25.3, P = 0.0001; I^2^ = 84%).

Sensitivity analysis by the methodological quality of the trials was not carried out because all trials were double-blind, which also means that all used concealed allocation. One trial used consecutive allocation \[[@R28]\], but in a double-blind trial it is not reasonable to assume that consecutive allocation would lead to systematic bias between the study groups. Furthermore, the trial \[[@R28]\] had low dose of zinc and therefore its exclusion would strengthen, and not weaken, the evidence that zinc lozenges differ from the placebo.

All three trials which used zinc acetate in doses higher than 75 mg/day (Table **[3](#T3){ref-type="table"}**) were methodologically rigorous randomized trials \[[@R21],[@R22],[@R25]\]. In the Petrus trial, only one participant was lost from follow-up \[[@R22]\]. In the first Prasad trial, two participants in the placebo group dropped out on day 2 \[[@R25]\], whereas there were no drop-outs in the second Prasad trial \[[@R21]\]. No sensitivity analysis was done in this subgroup.

There is substantial heterogeneity within the five high-dose non-acetate trials. Sensitivity analysis was done leaving out the Eby *et al*. \[[@R7]\] and Smith *et al*. \[[@R19]\] trials, which excluded a large number of randomized participants, 45% and 36%, respectively. Furthermore, over half of the common cold durations needed to be imputed to include these trials in Fig. (**[1](#F1){ref-type="fig"}**). When these two trials were excluded from the high-dose non-acetate subgroup, the remaining three trials lead to 22% (95% CI: 11 to 32%) decrease in the duration of colds. This confidence interval is essentially the same as that for all the five non-acetate trials, see above. Thus, exclusion of these two trials has no influence on conclusions.

DISCUSSION
==========

Dose-Response Relation Between the Quantity of Zinc and the Effect on the Common Cold Duration
----------------------------------------------------------------------------------------------

No effect of zinc lozenges was seen in trials where the total daily dose of zinc was less than 75 mg, whereas the majority of trials with higher zinc doses did find benefit (Tables **[1](#T1){ref-type="table"} to [3](#T3){ref-type="table"}**, Fig. **[1](#F1){ref-type="fig"}**). The level of 75 mg per day should not be considered as an exact biological limit, but as a pragmatic cut-off point for dichotomizing the trials into low and high dose trials in these meta-analyses. Nevertheless, the conclusion that zinc lozenges differ from the placebo does not depend on the arbitrary cut-off limit because pooling all the 13 double-blind comparisons also shows that zinc lozenges differ from the placebo (Table **[2](#T2){ref-type="table"}** and Fig. **[1](#F1){ref-type="fig"}**).

Lozenge Composition and the Level of Free Zinc Ions
---------------------------------------------------

In these meta-analyses, the dose-response relation was examined using the total daily zinc dose as the explanatory variable. However, this is a simplified approach because some lozenges contained substances which bind zinc ions tightly, such as citrate, tartrate or glycine, which decrease the level of free zinc ions. Thus, even though the same dose of zinc is used in two different lozenges, other constituents may lead to substantial differences in the levels of free zinc ions.

Previously, several authors discussed the availability of zinc ions as a factor that may potentially modify the effect of zinc lozenges on the common cold \[[@R8]-[@R15]\]. Martin assumed that sucking a zinc-citric acid lozenge would decrease the pH of saliva to 2.3, pointing out that citrate would not form a complex with zinc ion at such a low pH level \[[@R10]\]. However, Zarembo *et al*. carried out an experiment with 18 participants, finding that sucking a zinc-citric acid lozenge resulted in saliva pH levels ranging between 3.2 and 5.0 \[[@R15]\]. At such pH levels citrate binds zinc ions as shown by the published binding curves \[[@R10],[@R11],[@R13],[@R14]\].

The solution chemistry of zinc complexes gives further understanding of the differences between the zinc trials. Two research groups, both using lozenges containing 23 mg of elemental zinc, examined the effect of zinc lozenges on experimentally induced rhinovirus colds. Al-Nakib *et al*. \[[@R37],[@R38]\] found a significant benefit using the lozenges, whereas Farr *et al*. found none \[[@R39]\]. However, Farr\'s lozenge contained 2% citric acid whereas Al-Nakib\'s lozenge did not, a difference in lozenge composition which could explain the divergent results \[[@R11]-[@R14]\].

Among the trials with natural common cold episodes in Table **[1](#T1){ref-type="table"}**, Godfrey *et al*. \[[@R20]\] administered a high dose of zinc, but glycine in the lozenge bound 80% of the zinc ions to complexes \[[@R11]-[@R14]\], which could explain the rather small benefit compared with the other trials which used high doses of zinc (Table **[1](#T1){ref-type="table"}**). Turner *et al*. found no effect using 69 mg/day of zinc acetate \[[@R23]\]. However, Eby pointed out that Turner\'s lozenges contained palm kernel and cotton seed oils, and at the high temperature used in the manufacture of the lozenges, these ingredients react with zinc ions making insoluble compounds \[[@R40]\]. The lozenge used by Douglas *et al*. \[[@R26]\] contained tartaric acid, which binds zinc \[[@R11],[@R13],[@R14]\].

Although the solution chemistry of zinc ions may offer more detailed explanations of the variation between the trial results, the power of the dose-response analysis can be seen even by counting the total daily dosage of elemental zinc obtained from the lozenges (Tables **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**; Fig. **[1](#F1){ref-type="fig"}**).

Safety of Zinc
--------------

In several common cold trials, the zinc lozenges caused acute adverse effects, such as bad taste and constipation, but none of the trials reported long term harm. Furthermore, several of the reported adverse effects, in particular on taste, may have been caused by the specific lozenge composition, and may not reflect the effects of zinc ions per se \[[@R13]\]. In the most recent trial on zinc acetate, there were no significant differences between the zinc and placebo groups in the occurrence of adverse effects although the daily dose was 92 mg \[[@R21]\].

For certain patients, zinc has been administered at high doses, 150 mg/day, for therapeutic purposes for months or years \[[@R41]-[@R45]\]. Deficiency of copper has been reported as a consequence of long-term zinc supplementation \[[@R44],[@R45]\], but a six-week experiment did not find any effect from 150 mg/day of zinc on plasma copper levels \[[@R46]\]. On the basis of these long-term studies with high zinc doses, there does not seem to be any basis for assuming that treating the common cold for a week with high doses of zinc in the form of lozenges would cause unanticipated harm. A patient suffering from acute adverse effects such as bad taste can simply stop taking the lozenges.

Implications for Further Research
---------------------------------

Table **[1](#T1){ref-type="table"}** suggests that the benefit of zinc lozenges perhaps can be obtained with doses substantially lower than Eby *et al*. used in the first trial on the topic \[[@R7]\]. Four trials used 80 to 92 mg of zinc per day and observed significant benefit (Table **[1](#T1){ref-type="table"}**). Three of them used lozenges containing zinc acetate (Table **[3](#T3){ref-type="table"}**), which does not form complexes with zinc ions \[[@R13],[@R14]\]. Obviously, new trials should be carried out to confirm the benefit of zinc acetate lozenges at a dosage of about 80 mg per day, and to examine whether even lower daily doses in appropriately formulated lozenges might be effective.

Other Reviews on the Effect of Zinc Lozenges on the Common Cold
---------------------------------------------------------------

Two groups of reviewers concluded that there is no evidence that zinc lozenges are beneficial against colds. Jackson *et al*. \[[@R47],[@R48]\] found statistically significant heterogeneity between the zinc trials. They calculated a pooled estimate of effect, although the evidence of heterogeneity seriously challenges the validity of any single overall estimate. Faced with heterogeneous results, the main focus of the reviewers should be on trying to understand the sources of the heterogeneity \[[@R49]\]. Although Jackson suggested that some of the negative results might be explained by low zinc ion availability, they did not examine the issue.

In another systematic review, Caruso *et al*. used the quality scoring approach, so that for the trials identified they gave one point for each of 11 quality items if it was satisfied \[[@R50]\]. Only four of the identified trials obtained the maximum of 11 points, and Caruso *et al*. suggested that the positive findings in the zinc trials might be explained by methodological faults. However, such a quality scoring approach is discouraged, for example, in the Cochrane Handbook, which states that "the use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane reviews. While the approach offers appealing simplicity, it is not supported by empirical evidence" \[[@R18]\].

One major problem of quality scoring is the focus on reporting in contrast to the scientific quality of the trial. For example, Caruso *et al*. gave one point if the study reported "measurement of dropout rate". This means that a trial can report high dropout rate, indicating low scientific quality, yet Caruso *et al*. would allot a point because the high dropout rate was explicitly reported. Caruso *et al*. also gave a point for "double blinding" because "unblinded studies are biased towards finding a treatment effect" \[[@R50]\]. However, such a statement is invalid, because a large meta-analysis of controlled trials found no association between double blinding and the effect of intervention \[[@R51]\]. Most of Caruso *et al*.\'s other quality items involve similar problems. Furthermore, Caruso *et al*. did not discuss the possibility that the level of free zinc ions might have an effect on the trial results, nor did they refer to any of the numerous papers that have discussed this issue \[[@R8]-[@R15],[@R52]\].

Finally, both Jackson *et al*. \[[@R47],[@R48]\] and Caruso *et al*. \[[@R50]\] proposed that the benefit of zinc lozenges in some trials might be explained by the placebo-effect. To support their proposal, both groups referred to Chalmers' review on vitamin C and the common cold, which suggested that the differences between vitamin C and placebo groups were, paradoxically, caused by the placebo effect \[[@R53]\]. However, Chalmers\' review was shown to be erroneous over a decade ago. For example, the figures in his main table were not consistent with the original study reports and he made errors in calculation \[[@R30],[@R31],[@R54]\]. Thus, the conclusions about the effects of zinc lozenges in this study diverge from the conclusions of two earlier reviews, but there are explicit reasons for the divergence in the conclusions.

Goodwin and Tangum \[[@R16]\] argued that within academic medicine there has been systematic bias against the concept that under some conditions micronutrients might be beneficial at levels higher than the minimum required to avoid classic deficiency diseases. Dismissing the randomized double-blind trials in which zinc lozenges significantly reduced the duration of colds gives further support to their thesis.

While this paper was under review, a Cochrane systematic review on zinc and the common cold was published \[[@R55]\]. There are many differences between this paper and the Cochrane review. While this paper strictly limits to zinc lozenges, the Cochrane review combines zinc lozenge trials with ordinary zinc tablet trials. However, it is possible that benefits of zinc tablets \[[@R2]-[@R4]\] are caused by particularly low initial zinc intakes of the participants, whereas the effects of zinc lozenges may be caused by local effects in the oral cavity. Nevertheless, the Cochrane review also concluded that there is evidence of benefit of zinc administration.

CONCLUSIONS
===========

Controlled trials that have examined the effect of zinc lozenges on common cold symptoms have reported divergent results. This meta-analysis shows that a large part of the divergence can be explained by the variation in the total daily dose of zinc that the person obtained from the lozenges. Many trials with daily zinc doses of over 75 mg have found significant reduction in the duration of colds. Zinc lozenges have caused adverse effects, such as bad taste, but there is no evidence that they would cause long term harm. Since a large proportion of trial participants have remained without adverse effects, zinc lozenges might be useful for them as a treatment option for the common cold. More research is needed on zinc lozenges to find optimal lozenge compositions and treatment strategies.

SUPPLEMENTARY MATERIAL
======================

###### 

This article contains supplementary material and it can be viewed at publisher's website.

![The effect of zinc lozenges on the duration of the common cold. The trials are in the same order as in Table **[1](#T1){ref-type="table"}**, from the highest daily dose of zinc to the lowest dose. They are divided into the same high dose and low dose subgroups as in Table **[2](#T2){ref-type="table"}**. In the forest plot on the right side, the vertical line indicates the placebo level. The horizontal line indicates the 95% CI for the effect and the square in the middle of the horizontal line indicates the point estimate of the effect in the particular trial. Three diamond shapes indicate the pooled effects and their 95% CI:s for the two subgroups and for all trials. The duration of colds has been transformed to the relative scale so that the duration in the placebo group is given the value of 100%. Thereby the difference between zinc and placebo groups directly indicates the effect of zinc lozenges in percentages. See Supplementary Material 2 and Supplementary Material 3 for the extraction of the data and for the calculation of the relative mean and SD values for the common cold duration.](TORMJ-5-51_F1){#F1}

###### 

Effect of Zinc Lozenges on Common Cold Episodes of Natural Origin

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study \[Ref.\]                      No. of Participants            Zn Dose Per Day (mg)[a](#T1FN1){ref-type="fn"}   Average Duration of Colds (Days)[b](#T1FN2){ref-type="fn"} Zn/Placebo   The Effect of Zn                 P[b](#T1FN2){ref-type="fn"} (1-Tail)   --2×ln(P)
  ----------------------------------- ------------------------------ ------------------------------------------------ ----------------------------------------------------------------------- -------------------------------- -------------------------------------- -----------
  Eby *et al*.1984 \[[@R7]\]          65                             207                                              3.9/10.8[c](#T1FN3){ref-type="fn"}                                      -64%[c](#T1FN3){ref-type="fn"}   0.0005[c](#T1FN3){ref-type="fn"}       15.2

  Smith *et al*.1989 \[[@R19]\]       110                            207                                              5.9/6.3[d](#T1FN4){ref-type="fn"}\                                      -22%[d](#T1FN4){ref-type="fn"}   0.5[d](#T1FN4){ref-type="fn"}\         1.4
                                                                                                                      5.5/6.9[d](#T1FN4){ref-type="fn"}                                                                        0.01[d](#T1FN4){ref-type="fn"}         

  Godfrey *et al*. 1992 \[[@R20]\]    73                             192                                              4.9/6.1                                                                 -21%                             0.024                                  7.4

  Prasad *et al*. 2008 \[[@R21]\]     50                             92                                               4.0/7.1                                                                 -44%                             6×10^--13^                             56.3

  Petrus *et al*. 1998 \[[@R22]\]     101                            89                                               3.8/5.1                                                                 -26%                             0.0033                                 11.4

  Turner at al. A 2000 \[[@R23]\]     139                            80                                               6.0/5.5                                                                                                  0.5                                    1.4

  Mossad *et al*.1996 \[[@R24]\]      99                             80                                               4.4/7.6                                                                 -42%                             0.0005                                 15.2

  Prasad *et al*. 2000 \[[@R25]\]     48                             80                                               4.5/8.1                                                                 -44%                             2×10^--9^                              40.0

  Turner *et al*. B 2000 \[[@R23]\]   139                            69                                               5.5/5.5                                                                                                  0.5                                    1.4

  Douglas *et al*. 1987 \[[@R26]\]    58[e](#T1FN5){ref-type="fn"}   64                                               12.1/7.7                                                                                                 0.96                                   0.1

  Macknin *et al*. 1998 \[[@R27]\]    247                            45                                               9.0/9.0                                                                                                  0.5                                    1.4

  Weismann *et al*. 1990 \[[@R28]\]   130                            45                                               7/6                                                                                                      0.5                                    1.4

  Turner *et al*. C 2000 \[[@R23]\]   143                            30                                               6.0/5.5                                                                                                  0.5                                    1.4
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Calculation of the daily dose of zinc: see Supplementary Material 2.

The outcome is the mean or median of common cold duration, except when otherwise stated. The P-values were recalculated when appropriate data was reported in the paper.

Eby *et al.* \[[@R7]\] did not report the mean or median duration, but estimated the time at which half of the participants were cured from an exponential fit of the results. The P-value at this table was calculated by using the Fisher exact test for the number of participants reporting no symptoms after the 7-day trial: 32/37(86%) and 13/28(46%) in the zinc and placebo groups, respectively.

Smith *et al.* \[[@R19]\] reported that "subjects taking zinc gluconate had lower severity scores than those in the corresponding placebo group on days 4 to 7 of treatment. This difference is statistically significant (P = 0.02)." From Smith *et al.*'s fig. 2, the days needed for 80% reduction in the severity score, which occurred in the 4 to 7 day time range, was measured thereby transforming the effect to the time scale for this table. The upper line (5.9/6.3) gives the interpolated time point when 40% of participants had become asymptomatic from Smith *et al.*\'s fig. [1](#F1){ref-type="fig"}; the placebo participants were not followed until half of them had become asymptomatic. To be conservative, P = 0.5 was used for calculating the --2×log(P), and not the small P-value corresponding to the difference in severity scores on days 4 to 7.

The number of treatment courses was 63; some of the 58 participants had more than one cold episode.

###### 

The Effect of Zinc Lozenges on the Duration of the Common Cold: Combining the P-Values of the Placebo-Controlled Trials

  Trials Being Combined                                    No. of Trials   χ^2^    df   P
  -------------------------------------------------------- --------------- ------- ---- ----------
  All trials                                               13              154.0   26   10^--19^
  Low Zn dose (\<75 mg/day)                                5               5.7     10   0.8
  High Zn dose (\>75 mg/day)                               8               148.3   16   10^--22^
    Zn-acetate \[[@R21],[@R22],[@R25]\]                    3               107.7   6    10^--20^
    not Zn-acetate \[[@R7],[@R19],[@R20],[@R23],[@R24]\]   5               40.6    10   10^--5^

The P-values of the individual trials are combined by using the Fisher method (see the Methods section). The combined χ^2^ value is calculated from the --2×ln(P) values on the right side of Table **[1](#T1){ref-type="table"}**. The combined P-values are separately calculated for low dose and high dose trials. Finally, the high dose trials are divided to those which used zinc acetate and to those which used zinc salts other than acetate.

###### 

Pooling the Results of the High Dose Zinc Acetate Trials

  Trial                                                       Intervention   Effect of Zinc Acetate on Common Cold Duration[a](#T3FN1){ref-type="fn"} (95% CI)                             
  ----------------------------------------------------------- -------------- ----------------------------------------------------------------------------------- ------ ---- ------ ------ -------------------
  Petrus *et al*. 1998 \[[@R22]\][b](#T3FN2){ref-type="fn"}   52             3.80                                                                                1.63   49   5.10   2.96   -26% (-44%, -7%)
  Prasad *et al*. 2000 \[[@R25]\]                             25             4.5                                                                                 1.6    23   8.1    1.8    -44% (-56%, -33%)
  Prasad *et al*. 2008 \[[@R21]\]                             25             4.00                                                                                1.04   25   7.12   1.26   -44% (-53%, -35%)
  Pooled results                                              102                                                                                                       97                 -42% (-48%, -35%)

There is no evidence of heterogeneity over these three trials: χ^2^(2 df) = 3.5 (P = 0.2), I^2^ = 43%. Calculations were done by using the RevMan program \[[@R35]\].

Petrus *et al.* \[[@R22]\] reported the results inaccurately to only one decimal place, giving 3.8 and 5.1 for the mean duration of colds and 0.2 and 0.4 for the SE of the mean in the zinc and placebo groups, respectively. These more accurate figures were kindly provided by Ken Lawson (March 4, 2009).
